Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Part of paid clinical trials in Mobile, Alabama.

Sponsor
University of South Alabama
Study ID
NCT04230954
Phase
PHASE2
Status
Terminated

Conditions

  • Cervical Cancer
  • Metastatic Cervical Cancer
  • Persistent Cervical Cancer
  • Recurrent Cervical Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Drug: Cabozantinib Drug: Pembrolizumab

Key Dates

Start date
Apr 16, 2020
Status verified
Jun 2022
Primary completion
Feb 16, 2022
Completion
Feb 16, 2022

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib (XL 184) Plus Pembrolizumab
    A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Primary Outcome Measure

Progression Free Survival [ Time Frame: Up to 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of South Alabama Mitchell Cancer InstituteMobileAlabama36604-

Find similar trials in Mobile, AL

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of South Alabama Mitchell Cancer Institute· Mobile, AL

Related Studies